The company’s special fields are chemoprevention, clinical trials and genetictesting, all complementary fields.
In chemoprevention natural and synthetic substances are applied to stop, revert or delay the cancer process. Chemoprevention is Read-Gene’s main field. Inorder to keep its prevention programme on a possibly natural level, the companyhas developed the Read-Gene Anticancer Diet, the details of which will beavailable on a currently constructed company website. In the Read-Gene AnticancerDiet patients are given food with dosaged microelements and vitaminsselected according to their genetics to lower the risk of cancer.
The object of clinical trials is to ascertain whether a drug, preparation ortechnology is effective and safe. Read-Gene offers clinical trials to companies,mainly from the medical, pharmaceutical, chemical and biotechnological branches.What is ground-breaking in this programme is the fact that it focuses on patientswith a defined genetic profile. In two clinical trials cycles commissionedby pharmaceutical firms Read-Gene managed to recruit the largest number ofpatients worldwide, for which the company received commendation letters.
Genetic testing and genetic/cancer consulting are open to all patients. In December 2008 the company launched a web platform in Polish and English,through which genetic mutation tests can be ordered from all over the world. Genetictesting is an important part of Read-Gene’s work. It allows early diagnosisof cancer susceptibility and, in effect, the timely application of chemoprevention.
The company’s intellectual value includes five foreign and six domesticpatents, with more patent applications in process.
In February 2009 Read-Gene made a debut on the Warsaw Stock Exchange’sNew Connect floor, its stock value almost quadrupling over the following 13months.
